Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has received positive opinion from the Committee of Medicinal Products for Human Use (CHMP) of The European Medicines Agency regarding Gilenya (fingolimod) 0.5mg daily modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (MS) despite treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS.
Subscribe to our email newsletter
Novartis said Gilenya prevents the white blood cells from reaching the CNS, where they could potentially attack the protective covering around the nerve fibers, resulting in less inflammatory damage to the nerve cells.
The positive opinion was based on positive data from clinical studies evaluating the MS drug which showed efficacy in the reduction of relapses, the risk of disability progression, and the number of brain lesions detected by magnetic resonance imaging (MRI), a measure of disease activity.
Novartis Pharmaceuticals Division head David Epstein said they are pleased with CHMP’s recommendation because it means patients in Europe with highly active relapsing-remitting MS could soon benefit from Gilenya’s significant efficacy in a once-daily capsule.